Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith M Kerr

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Virchows Archiv : an International Journal of Pathology|July 20, 2022
Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessmentFrédérique Penault-Llorca, Keith M Kerr, Pilar Garrido, et al.
Nature Reviews. Clinical Oncology|February 13, 2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.
Virchows Archiv : an International Journal of Pathology|July 20, 2022
Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and managementFrédérique Penault-Llorca, Keith M Kerr, Pilar Garrido, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Histopathology|November 13, 2023
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologistsKeith M Kerr, Lukas Bubendorf, Fernando Lopez-Rios, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLCGareth H Williams, Andrew G Nicholson, David R J Snead, et al.
Thorax|November 5, 2015
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert GroupManfred Dietel, Lukas Bubendorf, Anne-Marie C Dingemans, et al.
Cancer Cytopathology|July 29, 2020
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimensLukas Bubendorf, Esther Conde, Federico Cappuzzo, et al.
Respirology (Carlton, Vic.)|October 6, 2010
Alveolar proteinosis with hypersensitivity pneumonitis: a new clinical phenotypeHema Verma, Andrew G Nicholson, Keith M Kerr, et al.
JCO Precision Oncology|September 24, 2025
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With CemiplimabJavier Perez, Keith M Kerr, Brian Baker, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Virchows Archiv : an International Journal of Pathology|July 20, 2022
Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessmentFrédérique Penault-Llorca, Keith M Kerr, Pilar Garrido, et al.
Nature Reviews. Clinical Oncology|February 13, 2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.
Virchows Archiv : an International Journal of Pathology|July 20, 2022
Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and managementFrédérique Penault-Llorca, Keith M Kerr, Pilar Garrido, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Histopathology|November 13, 2023
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologistsKeith M Kerr, Lukas Bubendorf, Fernando Lopez-Rios, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLCGareth H Williams, Andrew G Nicholson, David R J Snead, et al.
Thorax|November 5, 2015
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert GroupManfred Dietel, Lukas Bubendorf, Anne-Marie C Dingemans, et al.
Cancer Cytopathology|July 29, 2020
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimensLukas Bubendorf, Esther Conde, Federico Cappuzzo, et al.
Respirology (Carlton, Vic.)|October 6, 2010
Alveolar proteinosis with hypersensitivity pneumonitis: a new clinical phenotypeHema Verma, Andrew G Nicholson, Keith M Kerr, et al.
JCO Precision Oncology|September 24, 2025
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With CemiplimabJavier Perez, Keith M Kerr, Brian Baker, et al.
Pageof 12